{"id":3228,"date":"2013-04-19T11:00:00","date_gmt":"2013-04-19T11:00:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/interim-report-january-march-2013\/"},"modified":"2013-04-19T11:00:00","modified_gmt":"2013-04-19T11:00:00","slug":"interim-report-january-march-2013","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-march-2013\/","title":{"rendered":"Interim report January-March 2013"},"content":{"rendered":"
Strong sales growth and positive cash flow from operating activities<\/strong><\/div>\n<\/p>\n

FIRST QUARTER<\/span><\/strong><\/p>\n<\/p>\n

\u2022 Sales increased by 23 percent in local currency. Sales were the highest ever for an individual quarter and amounted to SEK 16.3 (13.8*) million, corresponding to an increase of 18 percent in SEK.<\/span><\/p>\n<\/p>\n

\u2022 Operating income before depreciation and amortization (EBITDA) amounted to SEK 3.8 (5.0*) million, corresponding to an EBITDA margin of 23 percent.<\/span><\/p>\n<\/p>\n

\u2022 Net income amounted to SEK 2.4 million, resulting in earnings per share of SEK 0.12.<\/span><\/p>\n<\/p>\n

\u2022 Cash flow from operating activities was SEK 4.0 million.<\/span><\/p>\n<\/p>\n

\u2022 In late March, the FDA responded with further supplementary questions regarding the application for marketing approval of STEEN Solution\u2122 on the American market. Xvivo plans to have its formal response to these questions submitted by the end of April\/beginning of May.<\/span><\/p>\n<\/p>\n

\u2022 The clinical study in the USA is proceeding according to plan with good clinical results. 36 of a planned 42 patients had received transplants by the end of the period. The company expects the study to be completed during the second quarter 2013.<\/span><\/p>\n<\/p>\n

\u2022 There continues to be a great deal of interest from clinics in the USA.<\/span><\/p>\n<\/p>\n

\u2022 Storage and distribution of products for Europe\/Asia has now been taken over by the company\u2019s own organization.<\/span><\/p>\n<\/p>\n

\u2022\u00a0<\/span>The sales and marketing organization has been enhanced with the appointment of a global sales and marketing director and a regional manager for Europe.<\/span><\/p>\n<\/p>\n

April\u00a019, 2013
<\/span>Gothenburg<\/span> <\/span><\/p>\n<\/p>\n

XVIVO Perfusion AB (publ)
<\/span>Magnus Nilsson, <\/span>CEO<\/span><\/p>\n<\/p>\n

* Comparative figures for 2012 are Vitrolife\u2019s Transplantation segment such as it was reported in Vitrolife\u2019s reporting<\/span><\/span><\/span><\/p>\n

\n

For further information please contact:
<\/span>
Magnus Nilsson, CEO, tel: +46 31 788 21 50, e-mail: magnus.nilsson@xvivoperfusion.com<\/span>
Christoffer Rosenblad, CFO, tel: +46 31\u00a0788 21 59, e-mail: christoffer.rosenblad@xvivoperfusion.com<\/a><\/span>
For further information on XVIVO Perfusion\u2019s business, please refer to the company\u2019s website, www.xvivoperfusion.com<\/a><\/span><\/p>\n

Xvivo Perfusion is required to publish the information in this press release in accordance with the Swedish Securities Market Act and\/or the Financial Instruments Trading Act. The information was submitted for publication on\u00a0April 19, 2013\u00a0at 1:00 p.m.<\/span><\/p>\n

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Strong sales growth and positive cash flow from operating activities FIRST QUARTER \u2022 Sales increased by 23 percent in local…<\/p>\n","protected":false},"template":"","class_list":["post-3228","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-regulatory-vpml","mfn-news-tag-mfn-report","mfn-news-tag-mfn-report-interim","mfn-news-tag-mfn-report-interim-q1","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-regulatory"],"acf":[],"yoast_head":"\nInterim report January-March 2013 - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-march-2013\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Interim report January-March 2013 - XVIVO\" \/>\n<meta property=\"og:description\" content=\"Strong sales growth and positive cash flow from operating activities FIRST QUARTER \u2022 Sales increased by 23 percent in local...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-march-2013\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/interim-report-january-march-2013\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/interim-report-january-march-2013\\\/\",\"name\":\"Interim report January-March 2013 - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2013-04-19T11:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/interim-report-january-march-2013\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/interim-report-january-march-2013\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/interim-report-january-march-2013\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Interim report January-March 2013\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Interim report January-March 2013 - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-march-2013\/","og_locale":"en_US","og_type":"article","og_title":"Interim report January-March 2013 - XVIVO","og_description":"Strong sales growth and positive cash flow from operating activities FIRST QUARTER \u2022 Sales increased by 23 percent in local...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-march-2013\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-march-2013\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-march-2013\/","name":"Interim report January-March 2013 - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2013-04-19T11:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-march-2013\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-march-2013\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-march-2013\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"Interim report January-March 2013"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3228","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3228"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}